John Dirksen
Psychiatry · Evans, GANPI 1679570147
Payments from drug & device makers
Across 221 payments — averaging $13.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alkermes, Inc.$259
- Sunovion Pharmaceuticals Inc.$224
- Takeda Pharmaceuticals U.S.A., Inc.$203
- Bausch Health US, LLC$162
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$155
- plus $881 from 20 others
What the payments were for
- Food & beverage$2,90598%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 108 | $1,068 |
| Alkermes, Inc. | 14 | $259 |
| Sunovion Pharmaceuticals Inc. | 11 | $224 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $203 |
| Bausch Health US, LLC | 9 | $162 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $155 |
| Adlon Therapeutics L.p. | 8 | $124 |
| Ironshore Pharmaceuticals Inc. | 6 | $101 |
| Idorsia Pharmaceuticals US Inc | 4 | $85 |
| Otsuka America Pharmaceutical, Inc. | 4 | $77 |
| Johnson & Johnson | 4 | $72 |
| Neos Therapeutics, LP | 4 | $65 |
| Brainsway USA Inc | 1 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| Corium, LLC | 6 | $35 |
| Supernus Pharmaceuticals, Inc. | 2 | $34 |
| Tris Pharma Inc | 2 | $34 |
| Lundbeck LLC | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Merck | 2 | $29 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| Aytu Biopharma, Inc. | 2 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $13 |
| Neuronetics, Inc. | 1 | $4 |
How this compares
$2,952 in reported general payments places this provider in the 80th percentile of 900 psychiatry providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 11 | $16,871 |
| Quetiapine Fumarate | 20 | $429 |
| Duloxetine Hcl | 14 | $320 |
| Sertraline Hcl | 12 | $215 |
| Lamotrigine | 12 | $203 |
| Fluoxetine Hcl | 19 | $169 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,068 | $16,87111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Evans
- Robert RiesenbergAtlanta$51.1M
- Saundra Maass-RobinsonAtlanta$11.1M
- David PurselleAtlanta$7.4M
- Maria JohnsonDecatur$5.4M
- Bethany DavisAtlanta$4.4M
- Michael BanovMarietta$4.2M
- Michael MobleySavannah$2.9M
- Richard PettyLoganville$2.9M
- Felipe SuplicyRome$2.3M
- Angelo SambunarisAlpharetta$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.